Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Donor lymphocyte infusions.

F Dazzi1, J Goldman

  • 1Department of Hematology, Imperial College School of Medicine, Hammersmith Hospital, London, United Kingdom. f.dazzi@ic.ac.uk

Current Opinion in Hematology
|November 5, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The use of MSCs in steroid-refractory acute GvHD in Europe: a survey from the EBMT cellular therapy & immunobiology working party.

Bone marrow transplantation·2025
Same author

Results from a phase Ib study of telisotuzumab vedotin in combination with osimertinib in patients with c-Met protein-overexpressing, EGFR-mutated locally advanced/metastatic non-small-cell lung cancer (NSCLC) after progression on prior osimertinib.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Thrombogenicity of biodegradable metals.

Bioactive materials·2024
Same author

Search for Gamma-Ray Spectral Lines from Dark Matter Annihilation up to 100 TeV toward the Galactic Center with MAGIC.

Physical review letters·2023
Same author

Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small-cell lung cancer: a pooled analysis.

Annals of oncology : official journal of the European Society for Medical Oncology·2022
Same author

Bounds on Lorentz Invariance Violation from MAGIC Observation of GRB 190114C.

Physical review letters·2020
Same journal

Dynamic myeloid suppressor states in cancer and inflammation and their therapeutic potential.

Current opinion in hematology·2026
Same journal

Factor XIa inhibition for the prevention of thrombosis: mechanism, clinical trial signals, and indication-specific positioning.

Current opinion in hematology·2026
Same journal

Nutrition as a regulator of hematopoietic stem cell biology and transplantation.

Current opinion in hematology·2026
Same journal

From biomimicry to clinical actionability: rethinking high-shear thrombosis as a mechanobiological system.

Current opinion in hematology·2026
Same journal

Bidirectional relationship between metabolic and thrombotic disease mechanisms.

Current opinion in hematology·2026
Same journal

The dual role of the brain-derived neurotrophic factor as a regulator of hemostasis and thrombotic risk.

Current opinion in hematology·2026
See all related articles

Donor lymphocyte infusions (DLI) effectively treat chronic myeloid leukemia relapse post-transplant. While less effective for acute leukemia and solid tumors, DLI shows promise for infectious complications and graft failure, with ongoing research to mitigate graft-versus-host disease.

Area of Science:

  • Hematology
  • Immunotherapy
  • Transplantation immunology

Background:

  • Allogeneic stem cell transplantation is a curative therapy for hematologic malignancies.
  • Relapse after transplantation remains a significant challenge.
  • Donor lymphocyte infusions (DLI) have emerged as a key strategy to overcome relapse and other complications.

Purpose of the Study:

  • To evaluate the efficacy and limitations of donor lymphocyte infusions (DLI) in managing complications following allogeneic stem cell transplantation.
  • To explore strategies for enhancing DLI effectiveness and mitigating adverse effects.
  • To assess the potential of DLI in treating various hematologic conditions and solid tumors.

Main Methods:

  • Review of clinical data and published literature on DLI therapy.

Related Experiment Videos

  • Analysis of response rates in different hematologic malignancies and solid tumors.
  • Investigation of adjunctive therapies, such as interleukin-2, to improve DLI efficacy.
  • Examination of methods to reduce graft-versus-host disease (GVHD) incidence.

    • Main Results:

    • DLI is highly effective for chronic myeloid leukemia relapse post-allogeneic stem cell transplantation.
    • DLI efficacy is limited in acute leukemia and other hematologic tumors, though interleukin-2 may enhance response.
    • DLI is established for treating post-transplant infectious complications and graft failure.
    • Novel administration regimens and cell manipulation techniques have reduced the incidence of graft-versus-host disease.

    Conclusions:

    • Donor lymphocyte infusions are a valuable tool in managing post-transplant relapse and complications, particularly in chronic myeloid leukemia.
    • Further research into DLI administration and cell manipulation is crucial for expanding its therapeutic applications and minimizing adverse events like GVHD.
    • DLI holds potential for treating solid tumors and infectious complications, warranting continued investigation.